sb 220025 has been researched along with Neoplasms in 1 studies
SB 220025: inhibits p38 mitogen-activated protein kinase; structure in first source
SB220025 : Am member of the class of imidazoles carrying piperidin-4-yl, 4-fluophenyl and 2-aminopyrimidin-4-yl substituents at posiitons 1, 4 and 5 respectively.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, H | 1 |
| Bahn, YJ | 1 |
| Jeong, DG | 1 |
| Woo, EJ | 1 |
| Kwon, JS | 1 |
| Ryu, SE | 1 |
1 other study available for sb 220025 and Neoplasms
| Article | Year |
|---|---|
Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Binding Sites; Chemistry, Pharmaceutical; Drug Design | 2008 |